cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2025-4448DQMUJScardiovascular-4448Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESРоль микроРНК в оценке сердечно-сосудистого риска у пациентов с семейной гиперхолестеринемиейRole of microRNA in assessing cardiovascular risk in patients with familial hypercholesterolemiahttps://orcid.org/0000-0002-5375-7328МихайлинаВ. И.MikhailinaV. I.

Виктория Игоревна Михайлина — м.н.с. отдела персонализированной диагностики, терапии и профилактики атеросклеротических сердечно-сосудистых заболеваний Института персонализированной терапии и профилактики.

Москва

Moscow

spandex2007@mail.ruhttps://orcid.org/0000-0003-4765-8021КиселеваА. В.KiselevaA. V.

Анна Витальевна Киселева — к.б.н., в.н.с., руководитель лаборатории молекулярной генетики Института персонализированной терапии и профилактики.

Москва

Moscow

sanyutabe@gmail.comhttps://orcid.org/0000-0001-9844-3122КуценкоВ. А.KutsenkoV. A.

Владимир Александрович Куценко — к.ф.м.н., с.н.с. отдела эпидемиологии хронических неинфекционных заболеваний, лаборатория биостатистики.

Москва

Moscow

vlakutsenko@ya.ruhttps://orcid.org/0000-0001-5989-6233МешковА. Н.MeshkovA. N.

Алексей Николаевич Мешков — д.м.н., руководитель Института персонализированной терапии и профилактики, помощник генерального директора по научной и клинической работе.

Москва

Moscow

meshkov@lipidclinic.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Оксана Михайловна Драпкина — д.м.н., профессор, академик РАН, директор.

Москва

Moscow

odrapkina@gnicpm.ruФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБУ "Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова" Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicine; Chazov National Medical Research Center of Cardiology20251108202524644484448Copyright © Михайлина В.И., Киселева А.В., Куценко В.А., Мешков А.Н., Драпкина О.М., 20252025Михайлина В.И., Киселева А.В., Куценко В.А., Мешков А.Н., Драпкина О.М.Mikhailina V.I., Kiseleva A.V., Kutsenko V.A., Meshkov A.N., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/4448

Наиболее распространенной наследственной формой дислипидемии и основной причиной преждевременных сердечно-сосудистых заболеваний является семейная гиперхолестеринемия. Это заболевание характеризуется высоким уровнем холестерина липопротеинов низкой плотности и, как следствие, ранним развитием коронарного атеросклероза и ишемической болезни сердца. Современные исследования все чаще фокусируются на роли малых некодирующих рибонуклеиновых кислот (РНК), в частности микроРНК, в регуляции липидного метаболизма и развитии атеросклеротических изменений. Цель настоящего обзора — проанализировать недавно опубликованные исследования, описывающие потенциальную роль микроРНК в оценке сердечно-сосудистого риска у пациентов с семейной гиперхолестеринемией.

The most common inherited form of dyslipidemia and the main cause of premature cardiovascular disease is familial hypercholesterolemia. This disease is characterized by high levels of low-density lipoprotein cho­lesterol and, as a consequence, early coronary atherosclerosis and coronary artery disease. Modern research increasingly focu­ses on the role of small non-coding ribonucleic acids (RNA), in particular microRNA, in the regulation of lipid metabolism and the develop­ment of atherosclerotic changes. The aim of this review was to analyze recently published studies describing the potential role of microRNA in assessing cardiovascular risk in patients with familial hypercholesterolemia.

микроРНКсемейная гиперхолестеринемияатеросклерозхолестерин липопротеинов низкой плотностиLDLRишемическая болезнь сердцаmicroRNAfamilial hypercholesterolemiaatherosclerosislow-density lipoprotein cholesterolLDLRcoronary artery diseaseReferencesMeshkov AN, Ershova AI, Kiseleva AV, et al. The prevalence of he­terozygous familial hypercholesterolemia in selected regions of the Russian federation: The FH-ESSE-RF study. J Pers Med. 2021;11:464. doi:10.3390/jpm11060464.Meshkov AN, Ershova AI, Kiseleva AV, et al. The prevalence of he­terozygous familial hypercholesterolemia in selected regions of the Russian federation: The FH-ESSE-RF study. J Pers Med. 2021;11:464. doi:10.3390/jpm11060464.Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recom­mendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S9-17. doi:10.1016/j.jacl.2011.03.452.Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recom­mendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S9-17. doi:10.1016/j.jacl.2011.03.452.Мешков А. Н., Михайлина В. И., Сметнев С. А. и др. Клинические проявления и эффективность гиполипидемической терапии у пациентки — двой­ной гетерозиготы с семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2023;3(52):53-8. doi:10.34687/2219-8202.jad.2023.03.0007.Meshkov AN, Mikhailina VI, Smetnev SA, et al. Clinical manifestations and efficacy of lipid-lowering therapy in a double hete­rozygous patient with familial hypercholesterolemia. Atherosclersis and dyslipidemias. 2023;3(52):53-8. (In Russ.) doi:10.34687/2219-8202.jad.2023.03.0007.Di Taranto MD, Fortunato G. Genetic heterogeneity of Familial Hypercholesterolemia: Repercussions for molecular diagnosis. Int J Mol Sci. 2023;24:3224. doi:10.3390/ijms24043224.Di Taranto MD, Fortunato G. Genetic heterogeneity of Familial Hypercholesterolemia: Repercussions for molecular diagnosis. Int J Mol Sci. 2023;24:3224. doi:10.3390/ijms24043224.Ежов М. В., Кухарчук В. В., Сергиенко И. В., и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Car­dio­logy. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.Сергиенко И.В, Мешков А. Н., Алиева А. С. и др. Возможности генетической диагностики для определения тактики лечения у пациентов с семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2023;4(53):5-17. doi:10.34687/2219-8202.jad.2023.04.0001.Sergienko IV, Meshkov AN, Alieva AS, et al. Possibilities of genetic diagnosis for determining treatment tactics in patients with familial hypercholesterolemia. Atherosclersis and dyslipidemias. 2023;4(53):5-17. (In Russ.) doi:10.34687/2219-8202.jad.2023.04.0001.Коновалов Г. А., Кухарчук В. В., Покровский С. Н. Экстракорпоральные методы лечения рефрактерных дислипидемий. Атеросклероз и дислипидемии. 2010;1(1):37-48.Konovalov GA, Kukharchuk VV, Pokrovskiy SN. Extracorporeal treat­ment of Refractory dyslipidemia. Atherosclersis and dyslipidemias. 2010;1(1):37-48. (In Russ.)EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398:1713-25. doi:10.1016/S0140-6736(21)01122-3.EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398:1713-25. doi:10.1016/S0140-6736(21)01122-3.Sohel MH. Extracellular/circulating MicroRNAs: Release mecha­nisms, functions and challenges. Achiev Life Sci. 2016;10:175-86. doi:10.1016/j.als.2016.11.007.Sohel MH. Extracellular/circulating MicroRNAs: Release mecha­nisms, functions and challenges. Achiev Life Sci. 2016;10:175-86. doi:10.1016/j.als.2016.11.007.O’Brien J, Hayder H, Zayed Y, et al. Overview of MicroRNA bioge­ne­sis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402. doi:10.3389/fendo.2018.00402.O’Brien J, Hayder H, Zayed Y, et al. Overview of MicroRNA bioge­ne­sis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402. doi:10.3389/fendo.2018.00402.Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35:3-11. doi:10.1055/s-0034-1397344.Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35:3-11. doi:10.1055/s-0034-1397344.Creemers EE, Tijsen AJ, Pinto YM. Circulating MicroRNAs: No­vel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483-95. doi:10.1161/circresaha.111.247452.Creemers EE, Tijsen AJ, Pinto YM. Circulating MicroRNAs: No­vel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483-95. doi:10.1161/circresaha.111.247452.Nishiguchi T, Imanishi T, Akasaka T. MicroRNAs and cardiovas­cu­lar diseases. Biomed Res Int. 2015;2015:682857. doi:10.1155/2015/682857.Nishiguchi T, Imanishi T, Akasaka T. MicroRNAs and cardiovas­cu­lar diseases. Biomed Res Int. 2015;2015:682857. doi:10.1155/2015/682857.de Gonzalo-Calvo D, Cenarro A, Garlaschelli K, et al. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. J Mol Cell Cardiol. 2017;106:55-67. doi:10.1016/j.yjmcc.2017.03.005.de Gonzalo-Calvo D, Cenarro A, Garlaschelli K, et al. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. J Mol Cell Cardiol. 2017;106:55-67. doi:10.1016/j.yjmcc.2017.03.005.Escate R, Padró T, Pérez de Isla L, et al. Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients. Atherosclerosis. 2024;392:117502. doi:10.1016/j.atherosclerosis.2024.117502.Escate R, Padró T, Pérez de Isla L, et al. Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients. Atherosclerosis. 2024;392:117502. doi:10.1016/j.atherosclerosis.2024.117502.Escate R, Padró T, Suades R, et al. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolemia patients. Cardiovasc Res. 2021;117(1): 109-22. doi:10.1093/cvr/cvaa039.Escate R, Padró T, Suades R, et al. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolemia patients. Cardiovasc Res. 2021;117(1): 109-22. doi:10.1093/cvr/cvaa039.Dlouha D, Blaha M, Huckova P, et al. Longterm LDL-apheresis treatment and dynamics of circulating miRNAs in patients with severe familial hypercholesterolemia. Genes. 2023;14:1571. doi:10.3390/genes14081571.Dlouha D, Blaha M, Huckova P, et al. Longterm LDL-apheresis treatment and dynamics of circulating miRNAs in patients with severe familial hypercholesterolemia. Genes. 2023;14:1571. doi:10.3390/genes14081571.Wu Y, Jiang L, Zhang H, et al. Integrated analysis of microRNA and mRNA expression profiles in homozygous familial hypercho­lesterolemia patients and validation of atherosclerosis associated critical regulatory network. Genomics. 2021;113:2572-82. doi:10.1016/j.ygeno.2021.05.036.Wu Y, Jiang L, Zhang H, et al. Integrated analysis of microRNA and mRNA expression profiles in homozygous familial hypercho­lesterolemia patients and validation of atherosclerosis associated critical regulatory network. Genomics. 2021;113:2572-82. doi:10.1016/j.ygeno.2021.05.036.Cione E, Mahjoubin-Tehran M, Bacchetti T, et al. Profiling of differentially expressed MicroRNAs in familial hypercholesterolemia via direct hybridization. Noncoding RNA Res. 2024;9:796-810. doi:10.1016/j.ncrna.2024.02.017.Cione E, Mahjoubin-Tehran M, Bacchetti T, et al. Profiling of differentially expressed MicroRNAs in familial hypercholesterolemia via direct hybridization. Noncoding RNA Res. 2024;9:796-810. doi:10.1016/j.ncrna.2024.02.017.Freitas RCC de, Bortolin RH, Kuraoka S, et al. Integrative ana­lysis of miRNAs and proteins in plasma extracellular vesicles of patients with familial hypercholesterolemia. Clin Chim Acta. 2025;568:120123. doi:10.1016/j.cca.2025.120123.Freitas RCC de, Bortolin RH, Kuraoka S, et al. Integrative ana­lysis of miRNAs and proteins in plasma extracellular vesicles of patients with familial hypercholesterolemia. Clin Chim Acta. 2025;568:120123. doi:10.1016/j.cca.2025.120123.Scicali R, Di Pino A, Pavanello C, et al. Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. Sci Rep. 2019;9:20354. doi:10.1038/s41598-019-56857-2.Scicali R, Di Pino A, Pavanello C, et al. Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. Sci Rep. 2019;9:20354. doi:10.1038/s41598-019-56857-2.Khan J, Lieberman JA, Lockwood CM. Variability in, variability out: best practice recommendations to standardize preanalytical variables in the detection of circulating and tissue microRNAs. Clin Chem Lab Med. 2017;55:608-21. doi:10.1515/cclm-2016-0471.Khan J, Lieberman JA, Lockwood CM. Variability in, variability out: best practice recommendations to standardize preanalytical variables in the detection of circulating and tissue microRNAs. Clin Chem Lab Med. 2017;55:608-21. doi:10.1515/cclm-2016-0471.Chan S-F, Cheng H, Goh KK-R, et al. Preanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs. J Mol Diagn. 2023;25:438-53. doi:10.1016/j.jmoldx.2023.03.005.Chan S-F, Cheng H, Goh KK-R, et al. Preanalytic Methodological Considerations and Sample Quality Control of Circulating miRNAs. J Mol Diagn. 2023;25:438-53. doi:10.1016/j.jmoldx.2023.03.005.Zhelankin AV, Iulmetova LN, Sharova EI. The Impact of the An­ti­coagulant Type in Blood Collection Tubes on Circulating Extra­cellular Plasma MicroRNA Profiles Revealed by Small RNA Se­quen­cing. Int J Mol Sci. 2022;23(18):10340. doi:10.3390/ijms231810340.Zhelankin AV, Iulmetova LN, Sharova EI. The Impact of the An­ti­coagulant Type in Blood Collection Tubes on Circulating Extra­cellular Plasma MicroRNA Profiles Revealed by Small RNA Se­quen­cing. Int J Mol Sci. 2022;23(18):10340. doi:10.3390/ijms231810340.Liu Y, Song J-W, Lin J-Y, et al. Roles of MicroRNA-122 in cardiovascular fibrosis and related diseases. Cardiovasc Toxicol. 2020; 20:463-73. doi:10.1007/s12012-020-09603-4.Liu Y, Song J-W, Lin J-Y, et al. Roles of MicroRNA-122 in cardiovascular fibrosis and related diseases. Cardiovasc Toxicol. 2020; 20:463-73. doi:10.1007/s12012-020-09603-4.Small EM, O’Rourke JR, Moresi V, et al. Regulation of PI3-kinase/Akt signaling by muscleenriched microRNA-486. Proc Natl Acad Sci USA. 2010;107:4218-23. doi:10.1073/pnas.1000300107.Small EM, O’Rourke JR, Moresi V, et al. Regulation of PI3-kinase/Akt signaling by muscleenriched microRNA-486. Proc Natl Acad Sci USA. 2010;107:4218-23. doi:10.1073/pnas.1000300107.Hsu A, Chen S-J, Chang Y-S, et al. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int. 2014;2014:418628. doi:10.1155/2014/418628.Hsu A, Chen S-J, Chang Y-S, et al. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed Res Int. 2014;2014:418628. doi:10.1155/2014/418628.Loyer X, Potteaux S, Vion A-C, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114:434-43. doi:10.1161/CIRCRESAHA.114.302213.Loyer X, Potteaux S, Vion A-C, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114:434-43. doi:10.1161/CIRCRESAHA.114.302213.Hametner B, Wassertheurer S, Mayer CC, et al. Aortic pulse wave velocity predicts cardiovascular events and mortality in patients undergoing coronary angiography: A comparison of invasive measurements and noninvasive estimates. Hypertension. 2021; 77:571-81. doi:10.1161/HYPERTENSIONAHA.120.15336.Hametner B, Wassertheurer S, Mayer CC, et al. Aortic pulse wave velocity predicts cardiovascular events and mortality in patients undergoing coronary angiography: A comparison of invasive measurements and noninvasive estimates. Hypertension. 2021; 77:571-81. doi:10.1161/HYPERTENSIONAHA.120.15336.Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med. 2014;33:1946-78. doi:10.1002/sim.6082.Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med. 2014;33:1946-78. doi:10.1002/sim.6082.

The authors declare that there are no conflicts of interest present.